To Study the effect of pharmacopoeial Unani medicine in the management of Anxiety

Evaluation of therapeutic effects of Majun Najah in the management of Izterab-i-Nafsani Umumi (Generalized Anxiety Disorder): An open label, block randomized, standard control study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105921

Enrollment

Registered

2026-03-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F411- Generalized anxiety disorder

Interventions

Intervention1: Majun Najah: It is a polyherbal pharmacopoeial unani medicine taken from NFUM. The formulation comprises of Post-e-Halayla Kabli (Terminalia chebula (Gaertn) Roxb.), Post-e-Balayla (Ter

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed patients of Generalised Anxiety Disorder (Izterab-i-Nafsani Umumi) based of subjective and objective parameters Patients in the age group of 18-60 years Patients irrespective of gender Patients who are ready to sign the informed consent, follow the protocol and willing to participate in clinical study voluntarily

Exclusion criteria

Exclusion criteria: Known cases of mental health disorders like panic disorder, Obsessive-compulsive disorder, post-traumatic stress disorder etc. Pregnant and lactating mother Patients with medical conditions like Uncontrolled diabetes mellitus and hypertension, cardiovascular disease, hepatic disease and renal disease Known cases of hyperthyroidism. Patients with severe anemia. Patient who fails to give written consent Patient who fails to follow up

Design outcomes

Primary

Measure	Time frame
1.Change from baseline to 46th day in Generalized Anxiety Disorder 7-item scale (GAD-7) 2.Change from baseline to 46th day in Hamilton Anxiety Rating Scale (HAM-A) and the Beck Anxiety Inventory (BAI). Timepoint: 1.Change from baseline to 46th day in Generalized Anxiety Disorder 7-item scale (GAD-7) 2.Change from baseline to 46th day in Hamilton Anxiety Rating Scale (HAM-A) and the Beck Anxiety Inventory (BAI).	—

Measure

Time frame

1.Change from baseline to 46th day in Generalized Anxiety Disorder 7-item scale (GAD-7) 2.Change from baseline to 46th day in Hamilton Anxiety Rating Scale (HAM-A) and the Beck Anxiety Inventory (BAI). Timepoint: 1.Change from baseline to 46th day in Generalized Anxiety Disorder 7-item scale (GAD-7) 2.Change from baseline to 46th day in Hamilton Anxiety Rating Scale (HAM-A) and the Beck Anxiety Inventory (BAI).

—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Aalie Jan

Regional research Institute of Unani Medicine, Srinagar

hussainzaffar6@gmil.com7006021996

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026